Literature DB >> 15864379

An improved technique for mitosis counting.

Rivka Gal1, Lea Rath-Wolfson, Yevgenia Rosenblatt, Marisa Halpern, Ariel Schwartz, Rumelia Koren.   

Abstract

Mitosis counting remains one of the most valuable prognostic indicators in tumor pathology; however, as currently carried out it is time consuming and not reproducible. In this study, 6 different pathologists, using different microscopes, arrived at widely different mitotic counts on the same slide, ranging from 4 to 16. These differences were mainly due to the different field areas of the various microscopes used and the method used for counting and recording. In evaluating the most active 10 HPF, the count ranged from 10 to 19. Instead, when an average of 40 fields was recorded, the range was 4-11. Using the mitosis/volume index, which expresses the number of mitotic figures per mm2 of viable tumor, the counts ranged from 8 to 10, a marked improvement. However, this method is complicated and not "user-friendly.'' We suggest a variation of the technique by which a 2 mm2 rectangle is drawn on a cover slip and mounted under the microscope, centered on the most mitotically active area of the tumor. The mitoses in that area are counted (=n) and the percent of viable tumor (=x%) is estimated under low magnification. The number of mitoses per mm2 of viable tumor (cs-MAI) is then calculated according to the formula Cs-MAI=100n/2x. Using this modified method, the range of mitoses counted by the different observers was very narrow (9 to 11), and the time required for the counting was only 5-10 minutes.

Entities:  

Mesh:

Year:  2005        PMID: 15864379     DOI: 10.1177/106689690501300206

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  9 in total

1.  Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.

Authors:  Heikki Joensuu
Journal:  Drugs       Date:  2012-10-22       Impact factor: 9.546

2.  SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis.

Authors:  Chao-Jie Wang; Zi-Zhen Zhang; Jia Xu; Ming Wang; Wen-Yi Zhao; Lin Tu; Chun Zhuang; Qiang Liu; Yan-Yin Shen; Hui Cao; Zhi-Gang Zhang
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

3.  Antibodies to placental immunoregulatory ferritin with transfer of polyclonal lymphocytes arrest MCF-7 human breast cancer growth in a nude mouse model.

Authors:  Marisa Halpern; Muayad A Zahalka; Leonid Traub; Chaya Moroz
Journal:  Neoplasia       Date:  2007-06       Impact factor: 5.715

4.  Standardization of whole slide image morphologic assessment with definition of a new application: Digital slide dynamic morphometry.

Authors:  Giacomo Puppa; Mauro Risio; Kieran Sheahan; Michael Vieth; Inti Zlobec; Alessandro Lugli; Sara Pecori; Lai Mun Wang; Cord Langner; Hiroyuki Mitomi; Takatoshi Nakamura; Masahiko Watanabe; Hideki Ueno; Jacques Chasle; Carlo Senore; Stephen A Conley; Paulette Herlin; Gregory Y Lauwers
Journal:  J Pathol Inform       Date:  2011-10-29

5.  A new scoring system using multiple immunohistochemical markers for diagnosis of uterine smooth muscle tumors.

Authors:  Lea Rath-Wolfson; Yevgenia Rosenblat; Marisa Halpern; M Herbert; I Hammel; Rivka Gal; M Leabu; Rumelia Koren
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

6.  Defining the area of mitoses counting in invasive breast cancer using whole slide image.

Authors:  Asmaa Ibrahim; Ayat G Lashen; Ayaka Katayama; Raluca Mihai; Graham Ball; Michael S Toss; Emad A Rakha
Journal:  Mod Pathol       Date:  2021-12-11       Impact factor: 8.209

7.  Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas.

Authors:  Birgitte Nielsen; Tarjei Sveinsgjerd Hveem; Wanja Kildal; Vera M Abeler; Gunnar B Kristensen; Fritz Albregtsen; Håvard E Danielsen
Journal:  Cytometry A       Date:  2014-12-05       Impact factor: 4.355

8.  Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.

Authors:  Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Jörg T Hartmann; Daniel Pink; Jochen Schütte; Giuliano Ramadori; Peter Hohenberger; Justus Duyster; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Maarit Sarlomo-Rikala; Bengt Nilsson; Harri Sihto; Karla V Ballman; Mika Leinonen; Ronald P DeMatteo; Peter Reichardt
Journal:  Cancer       Date:  2014-04-15       Impact factor: 6.860

Review 9.  Practical aspects of risk assessment in gastrointestinal stromal tumors.

Authors:  R L Jones
Journal:  J Gastrointest Cancer       Date:  2014-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.